The Mito-Frail Trial: Effects of MitoQ on Vasodilation, Mobility and Cognitive Performance in Frail Older Adults
Eligible age
65–80 yrs
Accepts
All genders
Locations
1 state
Healthy volunteers
Yes
See if you qualify for this study
Answer a few quick questions about your location and health. Takes about a minute.
About this study
The goal of this clinical trial is to test the effects of MitoQ supplementation in older adults and frail older adults with physical dysfunction and/or cognitive dysfunction. The main question\[s\] it aims to answer are: * To compare vascular function, oxidative stress levels, and physical and cognitive function among older adults and frail older adults with physical and cognitive dysfunction * To determine whether MitoQ supplementation has the potential to improve vascular function in central and cerebral vessels * To determine whether MitoQ supplementation can enhance physical and cognitive capabilities.
Sponsor: UConn Health
You may qualify if…
- ✓ men and women aged 65-80 with a slow gait speed (0.4m/s based on a 4m walk) and/or mild cognitive impairment.
- ✓ good cardiovascular health (not taking any blood pressure/flow/metabolism altering medications)
You may not qualify if…
- ✕ A vaccination in past two weeks
- ✕ Recent acute infection three weeks prior to enrollment
- ✕ Known immunodeficiency (including HIV infection, primary immunodeficiency, any history of chemotherapy or radiotherapy
- ✕ Use of medicines during past 6 months known to alter immune response such as high- dose corticosteroids
- ✕ Severe autoimmune disease requiring biological therapy
- ✕ Major severe illness and/or Hospitalization in past 3 months
- ✕ On warfarin or other medications that are considered a blood thinner
- ✕ Recent fall or other conditions that will impair ability to complete and/or interpret mobility performance test
Where it's recruiting
Farmington
Source: ClinicalTrials.gov · NCT06027554 · last updated 2026-01-09